ESC: Semaglutide Beneficial for HFpEF Patients With Obesity
TUESDAY, Aug. 29, 2023 -- For patients with heart failure with preserved ejection fraction and obesity, semaglutide is associated with a larger reduction in symptoms and physical limitations, according to a study published online Aug. 25 in the New...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Eating Disorders & Weight Management | Heart | Heart Failure | Obesity | Pharmaceuticals | Study